Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira's polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh experimental data expected to strengthen Altamira's intellectual property around its AM-401 nanoparticles for the treatment of KRAS-driven cancers HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based techn ...